 | | Vol. 14.20 – 26 May, 2022 |
| |
|
|
| Scientists demonstrated that XIST loss impaired the differentiation of human mammary stem cells and promoted the emergence of highly tumorigenic and metastatic carcinomas.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrated epithelial-to-mesenchymal transition and heterodimerized with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner.
[Science Advances] |
|
|
|
| Investigators reported an in vivo model based on xenografted zebrafish embryos where they selected for progressively invasive subpopulations of MDA-MB-231 breast cancer cells.
[Molecular Biomedicine] |
|
|
|
| Researchers showed that Kindlin-2, a focal adhesion protein, was critically involved in the promotion of androgen receptor signaling and breast cancer progression.
[Cell Death & Disease] |
|
|
|
| Scientists demonstrated that tumor necrosis factor receptor associated factor 4 (TRAF4) regulated Eg5 ubiquitination and contributed to Eg5-mediated breast cancer proliferation and inhibited breast cancer apoptosis.
[Frontiers in Oncology] |
|
|
|
| The authors assayed for, and observed, an association between Galectin-9 expression and invasiveness of breast cancer cells in vitro and in vivo.
[ACS Chemical Biology] |
|
|
|
| Investigators reported a small molecule, Carbazole Blue, that bound itself to DNA and inhibited cancer growth and metastasis by targeting DNA-related processes that tumor cells use but not the normal cells.
[Communications Biology] |
|
|
|
| Researchers found that G-protein-coupled receptor 110 (GPR110) was highly expressed in TNBC and GPR110 played a key role in TNBC progression by engaging the RAS signaling pathway, via Gαs activation.
[Cell Death Discovery] |
|
|
|
| Scientists investigated the mechanism of high-mobility group box 1 (HMGB1) through receptors for advanced glycation end products (RAGE) on cell migration/invasion and programmed death ligand 1 (PD-L1) expression in breast cancer cells.
[BMC Cancer] |
|
|
|
| The authors explored the expression of miR-379-5p and its mechanisms of affecting proliferation, migration, and invasion in breast cancer.
[Thoracic Cancer] |
|
|
|
|
High nuclear receptor corepressor 2 (NCOR2) in the tumors of patients with breast cancer predicted chemotherapy refractoriness, tumor recurrence and poor prognosis.
[Nature Cancer] |
|  | |
|
|
| Investigators discuss the function and highlight the existing inhibitors of histone deacetylase 3 in breast cancer pathogenesis and therapy.
[Medical Oncology] |
|
|
|
|
| Aileron Therapeutics announced it has treated the first patients in its Phase Ib randomized, controlled clinical trial evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities, as well as other toxicities in patients with p53-mutated breast cancer.
[Aileron Therapeutics, Inc.] |
|
|
|
| The Breast Cancer Society of Canada announced the recipients of their first-ever Breast Cancer Research request for proposals. Researchers from across Canada were invited to submit projects last December for funding consideration in 2022 and beyond.
[The Breast Cancer Society of Canada] |
|
|
|
|
| December 10 – 14, 2022
Maui, Hawaii, United States |
|
|
|
|
|
| | Institute of Cancer Research – London, England, United Kingdom |
|
|
|
| | Institute of Cancer Research – London, England, United Kingdom |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Oslo University Hospital – Oslo, Norway |
|
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
